Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals (AUPH) and Teva Pharmaceuticals (TEVA) recently settled their U.S. patent dispute over Aurinia's LUPKYNIS oral lupus nephritis drug. Teva acknowledged the validity and enforceability of Aurinia's patents covering LUPKYNIS, and agreed to delay generic entry into the market until December 7, 2036. This settlement eliminates generic competition from Teva for over a decade, allowing Aurinia to continue generating strong revenue from LUPKYNIS.

In Q2 2026, Aurinia reported total revenue of $83.2 million, a 19% year-over-year increase, and six-month revenue of $160.9 million, a 21% year-over-year increase. The settlement also supports Aurinia's current financial position, with robust free cash generation, expanding operating cash flows, and zero debt. However, Aurinia remains a single-product company, and faces ongoing litigation against other generic applicants.

Teva, on the other hand, operates on a larger scale and has diversified revenue streams, but is currently experiencing a drop in generic revenues due to competition from Revlimid. The settlement is a significant milestone for Aurinia, providing long-term protection and stability for the company's financial outlook.